Find It Endometrial panel references

 

Year                     2013

Title                     Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma.

Ref                       Am J Surg Pathol. 2013; 37:874-881.

PubMed ID:        23629444

 

 

Year                     2013

Title                     Histotype-genotype correlation in 36 high-grade endometrial carcinomas.

Ref                       Am J Surg Pathol. 2013; 37: 1421-1432.

PubMed ID:        24076778

 

Year                     2013

Title                     Integrated genomic characterization of endometrial carcinoma.

Ref                       Nature. 2013; 497: 67-73.

PubMed ID:        23636398

 

Year                     2015

Title                     A clinically applicable molecular-based classification for endometrial cancers.

Ref                       Br J Cancer. 2015; 113:299-310.

PubMed ID:        26172027

 

Year                     2017

Title                     Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer.

Ref                       Cancer 2017; 123(5): 802–813.

PubMed ID:        28061006

 

Year                     2019

Title                     Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series.

Ref                       Ann Oncol. 2018 May 1; 29(5):1180-1188

PubMed ID:        29432521

 

Year                     2016

Title                     Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: earlier prognostic information to guide treatment.

Ref                       Gynecol Oncol. 2016; 143:46-53.

PubMed ID:        27421752

 

Year                     2016

Title                     New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care.

Ref                       Gynecologic Oncology Research and Practice (2016) 3:14

PubMed ID:        27999680

 

Year                     2015

Title                     Just how accurate are the major risk stratification systems for early-stage endometrial cancer?

Ref                       Br J Cancer 2015; 112: 793–801.

PubMed ID:        25675149

 

Year                     2013

Title                     DNA polymerase epsilon and delta exonuclease domain mutations in endometrial cancer.    

Ref                       Hum Mol Genet 2013; 22: 2820–2828.

PubMed ID:        23528559

 

Year                     2014

Title                     Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication.

Ref                       Genome Res 2014; 24: 1740–1750

PubMed ID:        25228659

 

 

 

Year                     2015           

Title                     Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1.

Ref                       JAMA Oncol 2015; 1: 1319–1323.

PubMed ID:        26181000

 

Year                     2015

Title                     POLE proofreading mutations elicit an antitumor immune response in endometrial cancer.   

Ref                       Clin Cancer Res 2015; 21: 3347–3355.

PubMed ID:        25878334

 

Year                     2016

Title                     Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy.      

Ref                       Histopathology 2016; 68: 916–924.

PubMed ID:        26416160

 

Year                     2017

Title                     Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition.   

Ref                       Oncoimmunology 2017; 6: e1264565.

PubMed ID:        28344870

 

Year                     2015

Title                     Clinico pathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.             

Ref                       Mod Pathol 2015; 28: 505–514.

PubMed ID:        25394778

 

Year                     2009

Title                     Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3’exons of TACSTD1.

Ref                       Nat Genet 2009; 41: 112–117.

PubMed ID:        19098912

 

Year                     2017

Title                     Novel implications in molecular diagnosis of Lynch syndrome.              

Ref                       Gastroenterol Res Pract 2017; 2017: 2595098

PubMed ID:        28250766

 

Year                     2017

Title                     Comprehensive analysis of hypermutation in human cancer.   

Ref                       Cell 2017; 171: 1042–1056.e10.

PubMed ID:        29056344

 

Year                     2017

Title                     The genetic landscape of endometrial clear cell carcinomas.   

Ref                       J Pathol 2017 Oct; 243(2):230-241.

PubMed ID:        28718916

 

Year                     2016

Title                     Molecular genetic heterogeneity in undifferentiated endometrial carcinomas.        

Ref                       Mod Pathol 2016 Nov; 29 (11):1390-1398

PubMed ID:        27491810

 

Year                     2017

Title                     Frequent mismatch repair protein deficiency in mixed endometrioid and clear cell carcinoma of the endometrium.                 

Ref                       Int J Gynecol Pathol 2017; 36: 555–561.

PubMed ID:        28114191

 

Year                     2017

Title                     Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition.                   

Ref                       Oncoimmunology 2017; 6: e1264565

PubMed ID:        28344870

 

Year                     2016

Title                     Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts.              

Ref                       Clin Cancer Res 2016; 22: 4215–4224.

PubMed ID:        27006490

 

Year                     2015

Title                     A clinically applicable molecular-based classification for endometrial cancers.     

Ref                       Br J Cancer 2015; 113: 299–310.

PubMed ID:        26172027

 

Year                     2017

Title                     Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival.       

Ref                       Gynecol Oncol 2017; 146: 588–595

PubMed ID:        28709704

 

Year                     2016

Title                     Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts.              

Ref                       Clin Cancer Res 2016; 22: 4215–4224.

PubMed ID:        27006490

 

Year                     2015

Title                     Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative.             

Ref                       Mod Pathol 2015; 28: 836–844.

PubMed ID:        25720322

 

Year                     2016

Title                     Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.

Ref                       Clin Cancer Res. 2016 Aug 15;22(16):4215-24.

PubMed ID:        27006490

 

Year                     2018

Title                     The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses.

Ref                       J Pathol 2018; 244: 538–549.

PubMed ID:        29344951

 

Year                     2016

Title                     PORTEC-4a: Randomised Trial of Standard or Molecular Profile-Based Recommendation for Radiotherapy after Surgery for Women with Early Stage Endometrial Cancer;

Ref                       2016 Jun 01. [Accessed 20 December 2017]. Available from: https://www.isrctn .com/ISRCTN11659025

PubMed ID:       

 

Year                     2018

Title                     Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC4a trial. 

Ref                       Gynecologic Oncology 151 (2018) 69–75.

PubMed ID:        30078506

 

Year                     2017

Title                     Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 Study.              

Ref                       J Clin Oncol 2017; 35: 2535–2541.          

PubMed ID:        28489510

 

Year                     2015

Title                     Prognostic significance of pole proofreading mutations in endometrial cancer.      

Ref                       J. Natl Cancer Inst. 2015; 107; 402

PubMed ID:        25505230

 

 

 

Year                     2014

Title                     POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.                             

Ref                       Gynecol. Oncol. 2014; 134; 15–19.          

PubMed ID:        24844595

 

Year                     2016

Title                     Endometrial carcinomas with pole exonuclease domain mutations have a favorable prognosis.            

Ref                       Clin. Cancer Res. 2016; 22; 2865–2873.

PubMed ID:        26763250

 

Year                     2016

Title                     Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.     

Ref                       J. Clin. Invest. 2016; 126; 2334–2340.

PubMed ID:        27159395

 

Year                     2016

Title                     Regression of chemotherapy-resistant polymerase epsilon (POLE) ultra-mutated and MSH6 hyper-mutated endometrial tumors with nivolumab.         

Ref                       Clin. Cancer Res. 2016; 22; 5682–5687.

PubMed ID:        27486176

 

Year                     2014

Title                     Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma.               

Ref                       J Natl Cancer Inst 2014; 106: pii: dju245.

PubMed ID:        25214561

 

Year                     2017

Title                     CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence.   

Ref                       Mod Pathol 2017; 30: 1032–1041.

PubMed ID:        28281553

 

Year                     2016

Title                     L1CAM expression in endometrial carcinomas: an ENITEC collaboration study.  

Ref                       Br J Cancer 2016; 115: 716–724.

PubMed ID:        27505134

 

Year                     2017

Title                     Expression of L1CAM in curettage or high L1CAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients.           

Ref                       Br J Cancer 2017; 117: 840–847.

PubMed ID:        28751757

 

Year                     2016

Title                     Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.   

Ref                       Mod Pathol 2016; 29: 174–181.

PubMed ID:        26743472

 

Year                     2014

Title                     L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results.    

Ref                       Eur J Cancer 2014; 50: 2602–2610.

PubMed ID:        25126672

 

Year                     2013

Title                     L1CAM in early-stage type endometrial cancer: results of a large multicentre evaluation.     

Ref                       JNatl Cancer Inst 2013; 105: 1142–1150.

PubMed ID:        23781004

 

Year

Title                     Review. Incorporation of molecular characteristics into endometrial cancer management.

Ref                       Histopathology 2020, 76, 52–63.

PubMed ID:        31846532